[{"orgOrder":0,"company":"Novotech","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Biolexa","moa":"30S ribosomal subunit","graph1":"Dermatology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol Valine Hemisuccinate","moa":"CB1\/CB2 receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Novotech \/ Skye Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Novotech \/ Skye Bioscience"},{"orgOrder":0,"company":"Novotech","sponsor":"Dren Bio","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"DR-0201","moa":"CD20","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Dren Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"DR-0201","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Krystal Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Panaphix","moa":"Cytokine","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Novotech \/ Undisclosed"},{"orgOrder":0,"company":"Novotech","sponsor":"Nexel","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"NP-011","moa":"ERK","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"LYT-300","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"AceLink Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Calithera Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Telaglenastat","moa":"Glutaminase kidney isoform, mitochondrial","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"CytoAgents","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"GP1681","moa":"GPCR","graph1":"Immunology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Deupirfenidone","moa":"IL-6 \/TNF-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TO-O-1001","moa":"LSD1","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Pasithea Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Escient Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EP547","moa":"MRGPX4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"OliPass","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLP-1002","moa":"NaV1.7 channel","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"OliPass","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"OLP-1002","moa":"NaV1.7 channel","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"OliPass","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SOUTH KOREA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"OLP-1002","moa":"NaV1.7 channel","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Invivyd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"VYD2311","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"EYEGENE","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"EG-COVID-003","moa":"SARS-CoV-2 spike protein","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Quadriga BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"QBS10072S","moa":"SLC7A5","graph1":"Oncology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Exonate","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EXN407","moa":"SRPK1-mediated VEGF splicing","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Spinogenix","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"SPG302","moa":"Synapses","graph1":"Neurology","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Autobahn Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABX-002","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Nanjing Immunophage Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"IPG7236","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AT02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ATB1651","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Intravacc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Avacc10 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CBT-009","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Curon Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CN1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Curon Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CN1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Curon Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CN202","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Dren Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DR-01","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DWRX-2003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Evaxion Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"EVX-02","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"JD Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GM-60106","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"JX09","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"KBL693","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Alphamab Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KN056","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Pharmosa Biopharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"L608","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Pharmosa Biopharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"L608","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Peg-Methug-Csf","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QG101-23-0","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Trivalent Poliomyelitis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Deoxycholate","moa":"Cell membrane||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TNB-738","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"VenatoRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VNRX-9945","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Vaxxinity","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VXX-401","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Invivyd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"10","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Invivyd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"10","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Xgene Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XG004","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"YBL-006","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"7","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Ripple Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"IBE-814","moa":"Unknown","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"9","companyTruncated":"Novotech \/ Novotech"},{"orgOrder":0,"company":"Novotech","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novotech \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Novotech \/ Novotech"}]

Find Clinical Drug Pipeline Developments & Deals by Novotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : PAS-004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neurofibromatosis 1.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 08, 2025

                          Lead Product(s) : PAS-004

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Recipient : Pasithea Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Nintedanib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : Nintedanib Esylate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : PureTech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Peg-Methug-Csf is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          November 21, 2024

                          Lead Product(s) : Peg-Methug-Csf

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : PharmaEssentia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : VYD2311 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          July 26, 2024

                          Lead Product(s) : VYD2311

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : Invivyd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : L608 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Arterial Hypertension.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 28, 2024

                          Lead Product(s) : L608

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Recipient : Pharmosa Biopharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : DR-0201 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          April 30, 2024

                          Lead Product(s) : DR-0201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Dren Bio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : PAS-004 is is a small molecule allosteric inhibitor of MEK 1/2. It is being evaluated for the treatment of neurofibromatosis type 1 and other cancer indications.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 13, 2024

                          Lead Product(s) : PAS-004

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Recipient : Pasithea Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : JX09 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypertension.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 27, 2023

                          Lead Product(s) : JX09

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Recipient : Ji Xing Pharmaceuticals Australia

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Recombinant Trivalent Poliomyelitis Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Poliomyelitis.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          October 26, 2023

                          Lead Product(s) : Recombinant Trivalent Poliomyelitis Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : CanSino Biologics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anaphylaxis.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          August 28, 2023

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Recipient : De Motu Cordis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank